Assay method and assay device using magnetic particles

The method uses magnetic particles to form and aggregate complexes with target and interfering analytes in complex samples, addressing performance issues by quantifying both analytes efficiently and accurately in a simplified, rapid process.

JP2024544416APending Publication Date: 2024-11-29HORIBA ABX SAS
View PDF 14 Cites 0 Cited by

Patent Information

Application Number
JP2024537441
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-21
Filing Date
2022-12-13
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Existing assay methods for complex samples, particularly whole blood, are compromised by cell presence, require cell lysis and washing, and are prone to non-specific signals, leading to decreased performance and increased complexity.

Method used

A method involving magnetic particles with specific receptors forms complexes with target and interfering analytes, applies magnetic fields to aggregate interfering complexes, and measures these aggregates to quantify both analytes, reducing steps and time to under 15 minutes.

Benefits of technology

The method ensures good analytical sensitivity without dilution, simplifies the test process, and accurately quantifies both target and interfering analytes, providing reliable results within 15 minutes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544416000001_ABST
    Figure 2024544416000001_ABST
Patent Text Reader

Abstract

A method for assaying a target analyte in a biological sample in a liquid medium is provided. [Solution] The present invention includes the steps of: contacting a biological sample with first magnetic particles 10 having a first receptor 101, and forming interference complexes through non-specific binding between the first magnetic particles and the target analyte; locally aggregating all complexes to form interference aggregates; erasing the first magnetic field and adding second magnetic particles 11 having a second receptor 111 to the liquid medium; measuring a first amount representing the amount of interference aggregates in the liquid medium and identifying the presence or absence of interference aggregates; applying a second magnetic field to bind the second magnetic particles to the first complexes to form second complexes 61; and measuring a second amount representing the total amount of interference aggregates and second complexes in the liquid medium, determining the amount of the second complex as a function of the first amount, and inferring the amount of the target analyte and the amount of interference analytes 30 present in the biological sample.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for assaying a target analyte in a liquid sample, and to an assay device intended to carry out this method.

[0002] The present invention relates generally to the field of assaying for molecules of interest that are soluble in a liquid medium, and in particular to the field of immunoassays for proteins, for example in whole blood samples. [Background technology]

[0003] In the prior art, assay methods have been proposed in which magnetic particles are used to capture and / or extract analytes present in a liquid sample. For this purpose, the magnetic particles carry one or more receptors specific for the target analyte, whereby the receptors can bind to the analyte to form a complex. The complex can then be captured by applying a magnetic field.

[0004] The applications of magnetic particle-based assays are wide-ranging. Some are aimed at oncology applications (see, for example, Xu, Hengyi, et al. “Antibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood”, Biomaterials 32.36 (2011): 9758-9765). Others are aimed at nucleic acid extraction applications, as described, inter alia, in US9976136 and Tan, Siun Chee, and Beow Chin Yiap. “DNA, RNA, and protein extraction: the past and the present” BioMed Research International, 2009.

[0005] Applications involving the extraction of nucleic acids typically involve a series of steps including lysing cells to release the nucleic acids, contacting the lysate with magnetic particles to capture the nucleic acids, application of a magnetic field (also referred to as "magnetization"), and washing steps, followed by elution of the nucleic acids (typically by a change in pH) and removal of the magnetic particles. The isolated nucleic acids can then be processed and assayed.

[0006] However, washing after cell lysis dilutes the sample, reducing capture performance, and the captured nucleic acids must be separated from the magnetic particles for processing, adding additional steps.

[0007] For other applications, such as diagnostics and oncology, the aim is to assay analytes directly in blood. Thus, the prior art proposes immunoassay methods that aim to assay proteins in whole blood samples. Known in particular are US6030845, US6855562 and US7326579, as well as EP2810042 by the present applicant. However, these methods also rely on an initial step of lysing the blood in order to destroy the cells. After lysis, a step of assaying the lysed sample by immunoagglutination (immune agglutination) is carried out. This lysis step allows agglutination measurements to be carried out under good conditions, but it dilutes the relatively large sample, which has a negative effect on the detection limit.

[0008] There are other immunoassay methods using magnetic particles, in particular the so-called homogeneous methods and the so-called heterogeneous methods.

[0009] The homogeneous method has the advantage of being able to omit the washing step. Homogeneous test methods are described in Baudry, Jean, et al. "Acceleration of the recognition rate between grafted ligands and receptors with magnetic forces", Proceedings of the National Academy of Sciences 103.44 (2006): 16076-16078 (Non-Patent Document 3), Ranzoni, Andrea, et al. "One-step homogeneous magnetic nanoparticle immunoassay for biomarker detection directly in blood plasma" Acs Nano 6.4 (2012): 3134-3141 (Non-Patent Document 4), and Aurich, Konstanze, et al. "Determination of the magneto-optical relaxation of magnetic nanoparticles as a homogeneous immunoassay", Analytical chemistry 79.2 (2007): 580-586 (Non-Patent Document 5). However, the lack of a washing step makes these assay methods difficult to apply to complex media such as blood, and indeed the presence of cells, especially in blood, greatly impedes the measurement.

[0010] Heterogeneous methods generally require a longer implementation time because they require a larger number of steps. Moreover, the implementation of the heterogeneous method is complicated. Kourilov, Vitaly, and Michael Steinitz, "Magnetic-bead enzyme-linked immunosorbent assay verifies adsorption of ligand and epitope accessibility," Analytical biochemistry 311.2 (2002): 166-170 (Non-Patent Document 6), describes the heterogeneous method.

[0011] Regardless of the assay method, there is a risk that a non-specific signal will be measured, specifically when at least one interfering analyte competes with the target analyte for binding to the magnetic particles or to a receptor specific for the target analyte.

[0012] Interfering analytes can be of various natures, such as proteins with a conformation similar to that of the target analyte, or molecules exhibiting a charge. More generally, interfering analytes can be any molecule that exhibits a non-negligible affinity for magnetic particles or receptors grafted onto the surface of magnetic particles. Therefore, the signal measured during the assay test is never zero. Thus, existing methods attempt to reduce the probability of non-specific signals. However, existing methods generally cannot distinguish between specific and non-specific signals. [Prior art documents] [Patent documents]

[0013] [Patent Document 1] U.S. Patent No. 9,976,136 [Patent Document 2] U.S. Patent No. 6,030,845 [Patent Document 3] U.S. Patent No. 6,855,562 [Patent Document 4] U.S. Patent No. 7,326,579 [Patent Document 5] European Patent Application Publication No. 2,810,042 [Non-Patent Document]

[0014] [Non-Patent Document 1] Xu, Hengyi, et al. “Antibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood”, Biomaterials 32.36 (2011): 9758 - 9765 [Non-Patent Document 2] Tan, Siun Chee, and Beow Chin Yiap. “DNA, RNA, and protein extraction: the past and the present” BioMed Research International, 2009 [Non-Patent Document 3] Baudry, Jean, et al. “Acceleration of the recognition rate between grafted ligands and receptors with magnetic forces”, Proceedings of the National Academy of Sciences 103.44 (2006): 16076 - 16078 [Non-Patent Document 4] Ranzoni, Andrea, et al. “One-step homogeneous magnetic nanoparticle immunoassay for biomarker detection directly in blood plasma” Acs Nano 6.4 (2012): 3134 - 3141 [Non-Patent Document 5] Aurich, Konstanze, et al. “Determination of the magneto-optical relaxation of magnetic nanoparticles as a homogeneous immunoassay”, Analytical chemistry 79.2 (2007): 580-586 [Non-Patent Document 6] Kourilov, Vitaly, and Michael Steinitz, “Magnetic-bead enzyme-linked immunosorbent assay verifies adsorption of ligand and epitope accessibility” Analytical biochemistry 311.2 (2002): 166-170 Summary of the Invention [Problem to be solved by the invention]

[0015] In conclusion, assay methods for complex samples, especially whole blood samples, are not satisfactory: the presence of cells in the sample, the need to lyse the cells and therefore at least one washing step, and the risk of non-specific signals can impair the performance of the method. [Means for solving the problem]

[0016] The present invention improves this situation. That is, the present invention provides: 1. A method for assaying a target analyte in a biological sample in a liquid medium, comprising: a. contacting the biological sample with first magnetic particles having a first receptor specific to a first attachment site of the target analyte, thereby forming a first complex by binding of the first magnetic particles to the target analyte, and if an interfering analyte is present in the sample, the contacting also results in the formation of an interfering complex by non-specific binding of the first magnetic particles to the interfering analyte; b. applying and maintaining a first magnetic field to locally aggregate all of the complexes formed in a. and, if any interference complexes are present, to aggregate the interference complexes together to form interference aggregates; c. removing the first magnetic field applied in step b. and adding to the liquid medium second magnetic particles having a second receptor specific for a second attachment site of the target analyte; d. measuring a first amount representative of the amount of interfering aggregates in the liquid medium to identify the presence or absence of the interfering aggregates; e. applying a second magnetic field to bind the second magnetic particles to the first complex to form a second complex; f. determining the amount of the second complex formed in step e. as a function of the first amount by measuring a second amount representative of the total amount of the interfering aggregates and the second complex in the liquid medium, and inferring therefrom the amount of target analyte present in the biological sample, and the amount of the interfering analyte, if any, present; The present invention relates to a method comprising:

[0017] Thus, according to the present invention, the presence or absence of interfering analytes in the biological sample can be verified. That is, if the biological sample contains both a target analyte and an interfering analyte, in step a., an interfering complex is formed by binding of the first magnetic particle with the interfering analyte. Thus, in step b., an aggregate of the interfering complexes is formed. Then, in step d., a quantitative measurement of the amount of the interfering aggregates formed is estimated. In step f., a calculation is performed to determine the amount of the target analyte and the amount of the interfering analyte present in the biological sample.

[0018] Furthermore, the method of the present invention does not involve excessive dilution, and as a result, good analytical sensitivity can be ensured. Moreover, the present invention reduces the number of steps, simplifying the entire test. Specifically, as a result, the time required is significantly reduced, to within about 15 minutes at most.

[0019] Of course, if no interfering analyte is present in the biological sample, the interfering complex, and thereby the interfering aggregate, will not be formed, and accordingly the amount measured in step d. will be zero or will not exceed the predetermined threshold.

[0020] Thus, the method of the present invention not only identifies the presence of interfering analytes in the biological sample, but also allows for the quantification thereof, and in conjunction with this, allows for the estimation of the amount of target analytes in the biological sample.

[0021] Step f. may include the substep of calculating the difference between the second amount measured in step f. and the first amount measured in step c. to determine the amount of the target analyte. In the main embodiment, in step c., second magnetic particles are added after or as the first magnetic field is turned off. The first amount, which represents the amount of interfering aggregates, is then measured in step d. In other embodiments, this measurement can be performed directly after turning off the magnetic field, i.e., before the second magnetic particles are introduced into the liquid medium (i.e., the reaction medium).

[0022] For the measurement of step f., i.e. for the measurement of the second amount representative of the total amount of the interfering aggregates and the second complexes, the second magnetic field is preferably eliminated beforehand from the measurement, which improves the measurement sensitivity.

[0023] To ensure specificity of the method of the invention, each first receptor is specific for a first attachment site of the target analyte and each second receptor is specific for a second attachment site different from the first attachment site of the target analyte. The flexibility afforded by the two different attachment sites allows the method of the invention to be rapidly adapted to different requirements depending on the nature of the application implemented.

[0024] In one particular embodiment of the invention intended to extract magnetic particles from said liquid medium, the magnetic field applied in step b. is equal to or greater than 100 mT and the holding of said magnetic field lasts for less than 5 minutes, preferably less than 3 minutes. In another particular embodiment, the application of said first magnetic field in step b. and said second magnetic field in step e. comprises a magnetization at 8 mT for 1 second, followed by three successive magnetization and cut-off sequences: 15 mT for 60 seconds, 0 mT for 28 seconds, 8 mT for 1 second, 0 mT for 1 second.

[0025] This allows the method of the invention to be carried out quickly, in particular in less than 15 minutes. Furthermore, the selected magnetization and interruption sequence can enhance the accuracy of the method of the invention, since it promotes the formation of complexes between the analyte and the magnetic particles, on the one hand, and allows a more accurate reading, on the other hand.

[0026] In a preferred embodiment, the measurements performed in steps d. and f. are selected from the group comprising measurements by transmittance turbidimetry, measurements by scattering turbidimetry and measurements by counting methods (especially analysis and / or image processing, flux), which allows for fast and reliable results.

[0027] In another embodiment, step a. comprises the substep of adding a diluent to dilute said biological sample, thereby making the ratio of said sample to said diluent equal to or greater than 1:10.

[0028] Specifically, this dilution reduces the viscosity of the medium, making it easier to capture the molecules to be assayed, i.e., promoting the formation of the first complex. The diluent may also contain a drug capable of reducing the probability of aggregation between the magnetic particles. For this purpose, a nonionic surfactant, an anionic surfactant, a cationic surfactant, an amphoteric surfactant, a protein (such as albumin, casein, gelatin, or an antibody), or a polymer (such as polyvinylpyrrolidone or polyvinyl alcohol) may be used.

[0029] In a particular embodiment, the application of the first magnetic field in step b. allows the extraction of the first complex from the liquid medium. In particular, this allows working with complex media (such as whole blood). Thus, in a particular embodiment, it is specifically provided that the biological sample is whole blood. One advantage of the present invention is that the steps of the method can be applied directly to blood samples, without the need for washing and / or dilution.

[0030] In another embodiment, step b. comprises removing the liquid medium and adding a reaction buffer. The reaction buffer may contain an anti-aggregation agent (nonionic surfactant, anionic surfactant, cationic surfactant, zwitterionic surfactant, protein or polymer) and / or a cell lysis agent (saponins, quaternary ammonium salts, sodium dodecyl sulfate, etc.). At least one washing step may be performed between removing the liquid medium and adding the reaction buffer. This washing step may further increase the specificity of the method of the present invention.

[0031] The anti-agglomerating agent is capable of dissociating any aggregates formed between magnetic particles, whereas the lysis agent is capable of lysing latent cells that were not expelled upon removal of the lysis agent from the liquid medium. It should be noted that the lysis agent does not require additional dilution of the sample, as opposed to prior art methods. In this embodiment, a more or less prolonged incubation can be performed to allow full action of the agents present in the reaction buffer.

[0032] Other advantages and features of the present invention will become apparent from the following detailed description and accompanying drawings. [Brief description of the drawings]

[0033] [Figure 1] FIG. 1 is a schematic diagram of the present invention. [Diagram 2] FIG. 2 is a diagram illustrating the principle of a first incubation step of first magnetic particles and a biological sample in the present invention. [Diagram 3] FIG. 2 is a principle diagram of the first magnetization step of the method of the present invention. [Figure 4] FIG. 2 is a diagram illustrating the principle of a second incubation step of second magnetic particles and a biological sample in the present invention. [Diagram 5] FIG. 2 is a diagram illustrating the principle of the second magnetization step of the method of the present invention. [Figure 6] FIG. 2 is a diagram illustrating the principle of a first incubation step of the first magnetic particles and a biological sample containing interfering molecules in the present invention. [Figure 7] FIG. 1 is a principle diagram of the first magnetization step in the method of the invention, applied to a biological sample containing interfering molecules. [Figure 8] FIG. 2 is a diagram illustrating the principle of the second incubation step of the present invention between the second magnetic particles and a biological sample containing interfering molecules. [Figure 9] 1 is a graph of optical density as a function of prostate specific antigen (PSA) concentration in a first example. [Figure 10] 12 is a graph of optical density as a function of antibody (Ac) concentration in the second example. [Figure 11] 12 is a graph of optical density as a function of antibody (Ac) concentration in the second example. [Figure 12] 10 is a graph of optical density as a function of anti-PCT (procalcitonin) antibody concentration in a third example. [Figure 13] 13 is a graph of optical density as a function of prostate specific antigen (PSA) concentration in a sixth example (not of the invention). [Figure 14] 1 is a graph of optical density as a function of prostate specific antigen (PSA) concentration in a seventh example (according to the present invention). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0034] The figures, tables and the following description essentially include configurations / components of a specific nature. The figures and tables are an integral part of this specification and therefore are not only used for a better understanding of the invention but also contribute to the definition of the invention, where appropriate.

[0035] The present invention generally relates to the identification of analytes in liquid biological samples. The sample may be of any suitable type, such as a bone marrow sample, cerebrospinal fluid, lymphatic fluid, urine, or preferably a whole blood sample. For example, the target analyte may be a protein, a nucleic acid, or any other molecule of interest present in the sample. The target analyte is present in very large amounts in the sample. That is, the sample may contain a target molecule that is present in very large copy numbers. That is, the concentration of the target analyte may be very high in the sample. This also applies to any other non-target analytes that may be present in the sample.

[0036] The present invention uses a technique in which target analytes are captured by magnetic particles whose surface is functionalized with ligands specific for each target analyte. These can consist of the types of particles mentioned above. The particle size of the magnetic particles used is generally between 5 nm and 10,000 nm, preferably between 100 nm and 500 nm.

[0037] In the assay method of the present invention, the first step a. comprises contacting the biological sample with first magnetic particles.

[0038] FIG. 1 is a schematic diagram of the present invention.

[0039] That is, the figure shows a schematic representation of one embodiment of the method of the invention. In a first step a., first magnetic particles are mixed in the presence of a buffer with a liquid biological sample in the presence or absence of a target analyte to be assayed. The biological sample may further, but not necessarily, contain interfering analytes.

[0040] First, the biological sample is contacted with first magnetic particles. Each magnetic particle has a receptor specific to the first attachment site of the target analyte, so that if the target analyte is present in the biological sample, a first complex is formed by binding between the first magnetic particles and the target analyte. If an interfering analyte is present in the sample, a interference complex is formed by non-specific binding between the first magnetic particles and the interfering analyte upon contact. Logically, if an interfering analyte is not present in the biological sample, no interference complex is formed.

[0041] In Fig. 2, a biological sample is shown that contains a liquid medium containing molecules. In Fig. 2, first magnetic particles 10 (PM1) are depicted that have specific receptors (herein called first receptors 101). These first magnetic particles 10 come into contact with the molecules to be assayed that are present in the biological sample. The molecules to be assayed will be called target analytes 20. The biological sample further contains other species or molecules 40, 50 (or interfering molecules 30, as will be explained later) that can be, for example, soluble molecules, cells or particles.

[0042] As a result of such contact in step a., the molecule 20 is captured by the first receptor 101. For this purpose, the first receptor 101 is made specific for the target analyte 20. To ensure good specificity, monoclonal antibodies or parts of antibodies are used as receptors. The binding of each receptor with each target analyte results in the formation of a complex, which is referred to in the present specification as a first complex C1. In other words, the association of the first magnetic particle 10 with the target analyte 20 results in the formation of a complex. These complexes are dispersed in a liquid medium.

[0043] The contacting in step a. may generally be carried out for about 10 minutes, preferably less than 5 minutes. Optionally, the liquid medium may be mixed or stirred during the incubation step to increase capture efficiency.

[0044] Step a. may include the substep of adding a diluent to dilute the biological sample, more particularly the liquid medium. In general, the dilution is selected to not exceed the initial concentration divided by 10 (i.e., 10-fold).

[0045] The method of the present invention then performs step b. of applying a first magnetic field. This allows all the complexes formed in step a. to be locally assembled, and allows the interfering complexes, if any, to be aggregated together to form interfering aggregates. It should be understood that locally assembling the complexes means organizing the complexes together in the liquid medium. The location can change depending on the applied magnetic field.

[0046] In fact, it should be noted that the main effect of this process b., and more specifically, the main effect of applying a magnetic field, is the formation of interfering aggregates, which are produced by the aggregation of interfering complexes with each other when they are formed in process a., in which the first magnetic particles are brought into contact with the biological sample.

[0047] In a particular embodiment of the present invention, the first magnetic particles are attracted to a magnet in the process. That is, the first complexes formed in step a., which are essentially formed from the association of the first magnetic particles with the target analyte, are attracted to the magnet. As a result, all the complexes formed in step a. are locally assembled to the magnet or to the environment near the magnet. This allows the first complexes to be isolated and separated from the liquid medium. That is, in this particular embodiment, the first complexes are extracted from the liquid medium of the biological sample. Logically, the separation of the first complexes from the liquid medium is only accomplished when the liquid medium is discharged later in the process. In this embodiment, the magnetic field can be maintained for a predetermined time, for example, 5 to 10 minutes, preferably less than 5 minutes, in step b. This facilitates good extraction of all the first complexes formed in step a. from the liquid medium.

[0048] 3 depicts magnetic particles 10 being attracted or organized according to a magnetic field B0 generated by a magnet. First complexes C1 are locally assembled.

[0049] In a particular embodiment, the liquid medium is removed from the biological sample and then a reaction buffer is added. That is, the liquid medium is replaced by a reaction buffer, which is also liquid. For this purpose, the liquid medium is first drained from a reaction vessel and then the reaction buffer is poured into the vessel. In this embodiment, a permanent magnet is generally provided that is capable of locally assembling the first complex C1 containing the target analyte 20 to itself. The target analyte molecules 20 bound to the receptor 101 are isolated and retained while the liquid medium is drained from the biological sample. The reaction buffer is added to replace the liquid medium.

[0050] In this embodiment, at least one wash may be performed between the removal of the liquid medium and the addition of the reaction buffer, which can increase the specificity of the method of the invention. During the wash steps, the magnetic field may be maintained or interrupted. In the latter case, after each wash, the magnetic field must be applied again for a certain period of time to recapture the suspended magnetic particles.

[0051] In one embodiment, the reaction buffer may contain at least one anti-agglomerating agent and / or at least one cell lysing agent. The anti-agglomerating agent is capable of dissociating aggregates or clumps of magnetic particles formed in step a. and / or step b., thereby improving the accuracy of the method of the present invention. The cell lysing agent is capable of lysing cells that were not removed by the removal of the liquid medium described above. It should be noted that, unlike the prior art methods, the lysing agent makes it unnecessary to carry out additional dilution of the sample.

[0052] In step c. of the method of the invention, the magnetic field B0 is removed. When the magnetic field is discontinued, the particles, complexes and any formed agglomerates disperse within the liquid medium.

[0053] 4 shows that the complex C1 is again in suspension. In step c., second magnetic particles 11 (PM2) carrying second receptors 111 specific for the target analyte 20 are further added to the liquid medium. At this stage, the second receptors 111 of the second magnetic particles 11 are not or barely bound to the target analyte 20. If necessary, the reaction medium can be stirred.

[0054] It should be noted that in general, the three-dimensional shape of the target analyte 20 allows a wide variety of different specific receptors 101, 111 to be selected. That is, every first receptor 101 is specific for a first attachment site on the target analyte 20, and every second receptor 111 is specific for a second attachment site on the target analyte, different from the first attachment site. This allows for increased specificity of the method of the invention. This flexibility provided by the two attachment sites also allows the method of the invention to be rapidly adapted to different requirements, in particular different requirements depending on the nature of the application to be carried out. That is, different receptors can be used depending on the target analyte to be assayed.

[0055] The method of the invention then includes step d. of determining the presence or absence of interfering aggregates by measuring a first amount representative of the amount of interfering aggregates in the liquid medium. If the measured amount is zero or below a predefined threshold, there are no (or only very few) interfering aggregates in the liquid medium. In this case, the principle that there are no (or only very few) interfering analytes in the biological sample can be considered. If the measured amount is not zero or is above the predefined threshold, there are interfering aggregates in the liquid medium, i.e. there are interfering analytes in the biological sample.

[0056] Specifically, the measurement may be performed by transmittance turbidimetry, scattering turbidimetry, or counting methods (analysis and / or image processing, flux, etc.).

[0057] In the method of the present invention, a second magnetic field is applied to bind the second magnetic particles 11, more specifically, the receptors 111 carried by the second magnetic particles, to the first complex C1 to form a second complex (step e). With regard to detectability, this second complex has the same detectability as the interfering aggregates, i.e., it is relatively easy to detect by optical density measurement or the like.

[0058] In Fig. 5, a second complex 61 is depicted, which is formed by applying a second magnetic field B1. The target analyte 20 is sandwiched between the first receptor of the first magnetic particle 10 and the second receptor of the second magnetic particle 11. In general, this step e. aims to generate chains or clumps of magnetic particles. The "sandwich" type complex or molecule formed by the first magnetic particle 10 and the second magnetic particle 11 separated by the target analyte 20 can be detected by various techniques, such as optical density measurement.

[0059] WO 2009 / 034271, FR2919390 and FR2959820 describe assay methods in which a series of cycles of application and interruption of a magnetic field is applied to a liquid reaction medium during the reaction of the magnetic particles with a target analyte, resulting in the formation of chains or clusters of magnetic particles. Each application of the magnetic field increases the number of bonds between the analyte and the magnetic particles, and each interruption of the magnetic field causes the unbound magnetic particles to disperse in the liquid medium. In the process, the number and / or size of the chains or clusters of bound particles increases. The transmission turbidity of the reaction medium increases proportionately. Measurement of the optical density of the medium after each interruption of the magnetic field thus allows the calculation of the concentration of the target analyte in the sample.

[0060] Other types of magnetic pulse sequences are possible, one example is described in Fast Magnetic Field-Enhanced Linear Colloidal Agglutination Immunoassay, Daynes et al. Anal. Chem. 2015, 87, 7583-7587.

[0061] In the present invention, the first magnetic field B0 applied in step b. may be the same as or different from the second magnetic field B1 applied in step e.

[0062] It may be advantageous to apply a magnetic field with different characteristics between these two steps. This is the case in the embodiment in which the extraction of the first complex from the liquid medium is performed. Under the above conditions, the magnetic field B0 of step b. must combine a significant strength (typically more than 100 mT) and a significant gradient in the magnetization direction to allow optimal capture of the first magnetic particles 10. In contrast, it is preferable to apply a magnetic field B1 of modest strength (typically less than 50 mT) and a gentle gradient in step e. The magnetic field B1 of step e. may also be applied in several pulses separated by relaxation periods. The duration and strength of these pulses may be variable.

[0063] In general, the application of the second magnetic field B1 preferably includes a number of magnetic pulses separated by rest periods. In one embodiment, this step e. includes magnetization at 8 mT for 1 second, followed by three successive magnetization and rest sequences: 15 mT for 60 seconds, 0 mT for 28 seconds, 8 mT for 1 second, and 0 mT for 1 second (8 mT: 1 second + 3 x (15 mT: 60 seconds + 0 mT: 28 seconds + 8 mT: 1 second + 0 mT: 1 second)).

[0064] Each pulse of 8 mT for 1 second essentially allows for a more accurate reading of the aggregation state of the particles (PM1) in the presence of interfering analytes. The pulse / pause sequence of 15 mT for 60 seconds → pause (0 mT) for 28 seconds → 8 mT for 1 second → pause (0 mT) for 1 second essentially allows for the formation of complexes.

[0065] The second complex 61 forms an aggregate that can be detected, for example, by optical density measurement, counting, etc. In general, the signal of the first complex is not significantly different from that of free magnetic particles due to the difference in size (and / or refractive index and / or magnetic moment) between the magnetic particles and the target analyte molecules, whereas the second complex is detectable because the target analyte binds to (is sandwiched between) two types of receptors and the magnetic particles aggregate with each other.

[0066] Thus, step f. of the method of the invention aims to determine the amount of the formed second complexes and therefrom to infer the amount of the target analyte present in the biological sample. For this purpose, step f. measures all aggregates, i.e. all second complexes and, if present, also interfering aggregates. This measurement finally makes it possible to determine the amount of the second complexes 61 formed in step e., specifically as a function of the amount of the interfering aggregates alone previously measured in step d. From the results thus determined, it is then possible to calculate the amount of the target analyte 20 present in the biological sample.

[0067] The present invention has the advantage that it is possible to identify not only the target analyte but also one or more interfering analytes.

[0068] The steps of the method in the presence of interfering analytes are described in detail below with reference to Figures 6, 7 and 8.

[0069] In this case, in step a. (see FIG. 6), not only are first complexes C1 formed, but also interference complexes Cint are formed by binding of the first magnetic particles 10 with the interference analytes 30. The interference complexes Cint are then dispersed in the liquid medium of the biological sample.

[0070] Generally, in step a, a magnetic particle 10 bearing a specific receptor 101 is contacted with a molecule 20 to be assayed in the presence of other species 30, 40, which can be soluble molecules, cells, particles, etc. Certain of these species (molecule 30 in FIG. 6) bind non-specifically to the first magnetic particle 10. The molecule 20 is nevertheless captured by the receptor 101.

[0071] In step b. (see FIG. 7), the first magnetic particles 10 are locally attracted or organized in the liquid medium according to the magnetic field B0 generated by the magnet. In the particular embodiment of the invention described above with reference to the extraction of magnetic particles, the liquid medium is replaced by the reaction buffer. In this particular case, it is preferable to use a permanent magnet (not shown) which attracts the magnetic particles.

[0072] In general, the molecules 20 (target analyte) bound to the receptor 101 and the molecules 30 non-specifically bound to the magnetic particles 10 are locally assembled in the liquid medium. The local assembly of the first complex C1 and the interfering complex Cint at a predetermined location in the liquid medium causes the first complex C1 and the interfering complex Cint to form a non-specific aggregate 60 (i.e., the interfering aggregate 60). Such a non-specific aggregate can also be formed by the aggregation of the interfering complexes Cint with each other. In general, the non-specific aggregate is formed in essentially the same manner as the complex of interest (i.e., a complex in which the complex Cint and the magnetic particle are adjacent to each other). The magnetic particles may be bound to the analyte molecules (C1) or the interfering molecules (Cint), or may be free particles (PM1). Such a non-specific aggregate 60 can be detected in the liquid medium, for example, by measuring the transmission turbidity (see FIG. 8).

[0073] The formation of the aggregates allows for quantitative measurement of the aggregates in the liquid medium in step d.

[0074] As mentioned above, in step f., the amount of the specific aggregate formed by the second complex is calculated using the measured amount obtained in step d. For this purpose, the calculation takes into account both the measured amount obtained in step d. and the measured amount obtained in step f. In this way, it is possible to deduce therefrom the amount of the target analyte present in the biological sample.

[0075] By measuring the agglutination state in step d., the risk of false positive results due to interference can be reduced. In the presence of such interfering molecules, the first magnetic particles 10 (PM1) may form non-specific agglutinations in step b. If step d. is omitted, such agglutinations would only be detected in step f., and it would be impossible to distinguish between the specific agglutinations caused by the presence of the molecule to be assayed (target analyte) and the non-specific agglutinations caused by the presence of another molecule (interfering analyte). By applying step d., it is possible to determine an initial agglutination threshold, for example, at which interferences cause no results, thereby avoiding erroneous results. One of the advantages of the present invention is that the amount of agglutination measured in step d. and the amount of agglutination measured in step f. can be used together to calculate an estimate of specific agglutination excluding non-specific agglutination.

[0076] Optionally, the method of the invention can be stopped after step d. If the measured amount of non-specific aggregates is too high and / or exceeds a predefined sensitivity threshold, the method of the invention can be interrupted after the measurement of step d. The method of the invention can then be restarted by selecting another receptor specific for the target analyte.

[0077] That is, in a particular embodiment of the invention, the method is stopped after step d., i.e. after measuring the first quantity representative of the amount of interfering aggregates in the liquid medium. For this purpose, it is possible to set a threshold value for the quantity at which the result is insufficiently sensitive, thereby avoiding further steps being carried out in vain or at least not useful, thus avoiding unnecessary costs and time losses. EXAMPLES

[0078] (Example)

[0079] To demonstrate the feasibility and sensitivity of the present invention, a first series of experiments (Examples 1-3) is performed.

[0080] Example 1

[0081] A PSA (Prostate Specific Antigen) assay test is carried out. Magnetic particles (200 nm carboxyl Adem beads; Ademtech) are functionalized with anti-PSA antibodies. A batch of particles is functionalized with a first clone (P4; ref. 7820-0370; Bio-Rad). Referring to the general description, these are the first magnetic particles (PM1). A second batch is functionalized with a second clone (214; ref. 7820-0217; Bio-Rad), which recognizes another epitope. Referring to the general description, these are the second magnetic particles (PM2). Purified PSA (ref. P3338; ​​Sigma-Aldrich) (10 nM) is diluted with various concentrations of horse serum (ref. H1270; Sigma-Aldrich) to form samples. Thus, the concentration of target PSA in the samples is known.

[0082] The samples are assayed as follows.

[0083] 71.5 μL of the sample are contacted with 1.5 μL of functionalized particles PM1(P4) (1%) for 2 min.

[0084] The medium is magnetized with a permanent magnet for 3 minutes and the supernatant is removed.

[0085] To the particles, 73.5 μL of HEPES buffer (50 mM, pH 7.5), F108 (0.8%), NaCl (800 mM), NaN3 (0.09%), and 1.5 μL of functionalized particles PM2 (214) (1%) are added.

[0086] The reaction medium thus formed is subjected to the following magnetic field sequence:

[0087] 8mT: 1 second + 3 × (15mT: 60 seconds + 0mT: 28 seconds + 8mT: 1 second + 0mT: 1 second)

[0088] The light intensity is measured when the reaction medium is irradiated with an RC-LED (650 nm) and the optical density difference (Dodiff3) before and after the application of a final pulse of intensity 8 mT is used as the signal to be measured.

[0089] The control measurement is carried out using the same samples and particles as above, but without the extraction step (see general description, step c.). A reaction medium consisting of 57 μL of HEPES buffer (50 mM, pH 7.5), F108 (0.8%), NaCl (800 mM), NaN3 (0.09%), 15 μL of said sample and 1.5 μL of each batch of functionalized particles is subjected to the same magnetic field cycle as above.

[0090] The results shown in Table 1 below are obtained as a function of the PSA concentration in the samples tested.

[0091] [Table 1]

[0092] FIG. 9 shows the Dodiff3 results and the corresponding curves as a function of PSA concentration.

[0093] It can be seen that the method according to the invention gives a signal which increases with the PSA concentration in the sample, with a higher activity than in the control test.

[0094] Example 2

[0095] A test is carried out that allows simulating the presence of interfering molecules in the sample of interest. Magnetic particles (200 nm carboxyl Adem beads; Ademtech) are functionalized with anti-PSA antibodies. A batch of particles (PM1) is functionalized with a first clone (P4, reference 7820-0370; Bio-Rad) and a second batch (PM2) with a second clone (214, reference 7820-0217; Bio-Rad) that recognizes another epitope. The sample is a NaCl solution (9 g / l) supplemented with an anti-mouse IgG antibody (Ac) (M8642; Sigma-Aldrich) that can bind nonspecifically to the anti-PSA antibody grafted onto the particles.

[0096] The samples are assayed as follows.

[0097] 71.5 μL of the sample are contacted with 1.5 μL of functionalized particles PM1(P4) (1%) for 2 min.

[0098] The medium is magnetized with a permanent magnet for 3 minutes and the supernatant is removed.

[0099] To the particles, 73.5 μL of HEPES buffer (50 mM, pH 7.5), F108 (0.8%), NaCl (800 mM), NaN3 (0.09%), and 1.5 μL of functionalized particles PM2 (214) (1%) are added.

[0100] The reaction medium thus formed is subjected to the following magnetic field sequence:

[0101] 8mT: 1 second + 3 × (15mT: 60 seconds + 0mT: 28 seconds + 8mT: 1 second + 0mT: 1 second)

[0102] The light intensity is measured when the reaction medium is irradiated with an RC-LED (650 nm), and the optical density difference (Dodiff3) before and after the application of the last pulse of intensity 8 mT is used as the signal to be measured. A similar signal (Dodiff0) is measured during the application of the first pulse of intensity 8 mT, allowing the agglutination of the medium before the application of the magnetic field to be measured.

[0103] The control measurement is performed using the same samples and particles as above, but without the extraction process. The reaction medium, consisting of 57 μL of HEPES buffer (50 mM, pH 7.5), F108 (0.8%), NaCl (800 mM), NaN3 (0.09%), 15 μL of the sample, and 1.5 μL of each batch of functionalized particles, is subjected to the same magnetic field cycle as above.

[0104] For pre-agglutination measurements, the results shown in Table 2 below are obtained as a function of the antibody concentration in the reaction medium.

[0105] [Table 2] FIG. 10 shows the results for Dodiff3 and the corresponding curves as a function of Ac concentration before aggregation.

[0106] In the control measurement, the signal before the application of the magnetic field does not depend on the concentration of the interfering antibody. On the other hand, when the magnetization step is added, the agglutination signal before the application of the magnetic field increases due to the addition of the interfering antibody, which makes it possible to consider a warning against such measurements.

[0107] For post-agglutination measurements, the following results, shown in Table 3 below, are obtained as a function of the antibody concentration in the reaction medium.

[0108] [Table 3] FIG. 11 shows the results of Dodiff3 and the corresponding curves as a function of Ac concentration after aggregation.

[0109] In either case, the agglutination signal increases in the presence of interfering antibodies, so without an initial measurement taken upon extraction it is not possible to determine whether the sample contains PSA or an interfering molecule.

[0110] Example 3

[0111] Tests will be carried out that can verify the applicability of the method of the present invention to whole blood samples.

[0112] Magnetic particles (200 nm carboxyl Adem beads; Ademtech) are functionalized with anti-PCT (procalcitonin) antibodies. A batch of particles (PM1) is functionalized with a first clone (E86813M; Meridian Life Sciences) and a second batch (PM2) is functionalized with a second clone (E01342M; Meridian Life Sciences) that recognizes a different epitope. Recombinant PCT (400 nM) is diluted in various concentrations of human blood to serve as samples. Thus, the concentration of target PCT in the samples is known.

[0113] The samples are assayed as follows.

[0114] Contact 71.5 μL of sample with 1.5 μL of functionalized particles (E86813M) (1%), 71.5 μL of HEPES buffer (50 mM, pH 7.5), F108 (0.8%), NaCl (800 mM), DTT (10 mM), and NaN3 (0.09%) for 2 min.

[0115] The medium is magnetized with a permanent magnet for 3 minutes and the supernatant is removed.

[0116] To the particles, 73.5 μL of HEPES buffer (50 mM, pH 7.5), F108 (0.8%), NaCl (800 mM), DTT (10 mM), NaN3 (0.09%), and 1.5 μL of functionalized particles (E01342M) (1%) are added.

[0117] The reaction medium thus formed is subjected to the following magnetic field sequence:

[0118] 8mT: 1 second + 3 × (15mT: 60 seconds + 0mT: 28 seconds + 8mT: 1 second + 0mT: 1 second)

[0119] The light intensity is measured when the reaction medium is irradiated with an RC-LED (650 nm) and the optical density difference (Dodiff3) before and after the application of a final pulse of intensity 8 mT is used as the signal to be measured.

[0120] The same test is performed on a plasma sample obtained from the blood sample. The blood sample is centrifuged at 1,500 g for 10 minutes to extract the plasma from the blood sample. Since the hematocrit of the blood sample is 40.4%, the expected PCT concentration in the plasma can be calculated as a function of the expected PCT concentration in the blood.

[0121] The results are obtained as shown in Table 4 (blood) and Table 5 (plasma) below.

[0122] [Table 4] [Table 5]

[0123] Figure 12 shows a graph of these results.

[0124] It should be noted that the signal measured as a function of the PCT concentration in the sample is independent of the nature of the latter, whether blood or plasma, which makes the described method applicable to whole blood samples.

[0125] A second series of experiments (Examples 4-7) is carried out to demonstrate the effect of interfering antibodies on magnetic particle agglutination.

[0126] For this purpose, agglutination measurements are carried out in the presence of various concentrations of anti-mouse antibodies, in order to simulate or mimic the effect of interfering antibodies.

[0127] In this series of experiments particles (200 nm Adem beads) functionalized with antibody P4 (reference number 7820-0370: Bio-Rad) or with antibody 214 (reference number 7820-0217: Bio-Rad) are used.

[0128] Example 4: Measurements not including PSA

[0129] In this embodiment, the first and second magnetic particles (PM1, PM2) are simultaneously introduced into a liquid medium, and therefore this embodiment is not an embodiment according to the present invention.

[0130] In the first step, a standard cycle of steps is carried out. The prepared sample contains: - 57 μL of HEPES buffer (50 mM, pH 7.5), F108 (0.8%) and NaCl (800 mM); - 15 μL of NaCl solution (9 g / l) containing the desired concentration of anti-mouse antibody (M8642; Sigma-Aldrich); - 3 μL of particles (P4) (1 w / v% (mass to volume ratio concentration or p / v (mass per unit volume))); and -3 μL of particles (214) (1 w / v%).

[0131] The following cycle (Cagg) is then applied to the sample:

[0132] 8mT: 1 second + 3 × (15mT: 60 seconds + 0mT: 28 seconds + 8mT: 1 second + 0mT: 1 second)

[0133] The optical density difference of each sample before and after the first pulse of intensity 8 mT (Dodiff0) can be measured as an indication of the initial particle agglutination level. The optical density difference before and after the last pulse of intensity 8 mT (Dodiff3) or the optical density difference between the end and start of the Cagg cycle (ΔDO) can be measured as the final agglutination level.

[0134] The results shown in Table 6 are obtained as a function of the antibody (Ac) concentration in the reaction medium.

[0135] [Table 6] The Dodiff3 and ΔDO increase with the concentration of the introduced antibody, indicating that the selected antibody causes interference, whereas the Dodiff0 measurement does not change significantly with the antibody concentration, and therefore does not signal interference.

[0136] Example 5: Measurements not including PSA

[0137] The prepared samples include: - 57 μL of HEPES buffer (50 mM, pH 7.5), F108 (0.8%) and NaCl (800 mM); - 15 μL of NaCl solution (9 g / l) containing the desired concentration of anti-mouse antibody (M8642; Sigma-Aldrich); and -3 μL of particles (P4) (1 w / v%)

[0138] After applying the Cagg cycle (details as above) to the sample, 3 μL of particles (214) (1% w / v) are added to the medium and the Cagg cycle is applied again.

[0139] In the first cycle, the same indicators as above (Dodiff0 1 , Dodiff3 1 , ΔD 1 ) was measured for the particle (P4) alone, and in the second cycle, the same index as above (Dodiff0 2, Dodiff3 2 , ΔD 2 ) can be measured for all particles. The results are shown in Table 7 below.

[0140] [Table 7] ΔDO 2 or Dodiff3 2 The indicator of ΔDO increases with input antibody concentration. However, in this procedure, the presence of aggregates before the application of the second cycle, which is related to interference in the sample, is measured by ΔDO 1 or Dodiff3 1 That is, in this embodiment, if the threshold value is set to 5 mDO, it is possible to detect a sample containing interfering antibodies.

[0141] Example 6: PSA dose response curve

[0142] In this embodiment, the first and second magnetic particles (PM1, PM2) are simultaneously introduced into a liquid medium, and therefore this embodiment is not an embodiment according to the present invention.

[0143] First, a dose response curve is plotted in the absence of interfering antibody.

[0144] The samples consisted of: - 57 μL of HEPES buffer (50 mM, pH 7.5), F108 (0.8%) and NaCl (800 mM); - 15 μL of NaCl solution (9 g / l) containing the desired concentration of PSA (P3338; ​​Sigma-Aldrich); - 3 μL of particles (P4) (1 w / v%); and -3 μL of particles (214) (1 w / v%).

[0145] After applying the Cagg cycle, the results shown in Table 8 below are obtained.

[0146] [Table 8] Then, a dose-response curve is plotted when anti-mouse antibody is added.

[0147] For this purpose, the sample consists of: - 57 μL of HEPES buffer (50 mM, pH 7.5), F108 (0.8%) and NaCl (800 mM); - 15 μL of NaCl solution (9 g / l) containing the desired concentration of PSA (P3338; ​​Sigma-Aldrich) and anti-mouse antibody (5 nM); - 3 μL of particles (P4) (1 w / v%); and -3 μL of particles (214) (1 w / v%).

[0148] The antibody concentration in the reaction medium is therefore 1 nM. After application of the Cagg cycle, the results shown in Table 9 below are obtained.

[0149] [Table 9]

[0150] FIG. 13 shows these results graphically.

[0151] The Dodiff0 value does not change significantly with or without anti-mouse antibodies, which means that the presence of an interfering molecule is not predictive. Instead, this molecule leads to an overestimation of the Dodiff3 and ΔDO values. In other words, if the ΔDO value measured in the presence of the antibody used as the standard curve is reported on a dose-response curve in the absence of the antibody, this would lead to an overestimation of the PSA titer. For example, a sample without PSA would have an assay result of about 5 nM, and a sample with PSA (1 nM) would have a titer of over 8 nM.

[0152] Example 7: PSA dose response curve

[0153] First, a dose response curve is plotted in the absence of interfering antibody.

[0154] The samples consisted of: - 57 μL of HEPES buffer (50 mM, pH 7.5), F108 (0.8%) and NaCl (800 mM); 15 μL of NaCl solution (9 g / l) containing the desired concentration of PSA (M8642; Sigma-Aldrich); and - 3 μL of particles (P4) (1 w / v%).

[0155] After the Cagg cycle is applied to the sample, 3 μL of particles (214) (1% w / v) are added to the medium and the Cagg cycle is applied again.

[0156] The results, shown in Table 10 below, are obtained as a function of the amount of PSA present in the reaction medium.

[0157] [Table 10] It can be seen that the values ​​of Dodiff3 and ΔDO after the second aggregation cycle increase with the amount of PSA as expected, whereas the values ​​of Dodiff3 and ΔDO after the first aggregation cycle do not change significantly since specific aggregates are only formed between particles with antibody P4 and particles with antibody 214. Thus, no warning would be generated for these samples if the threshold remained at 5 mDO as above.

[0158] Then, a dose-response curve is plotted when anti-mouse antibody is added.

[0159] The samples consisted of: - 57 μL of HEPES buffer (50 mM, pH 7.5), F108 (0.8%) and NaCl (800 mM); - 15 μL of NaCl solution (9 g / l) containing the desired concentration of PSA (M8642; Sigma-Aldrich) and anti-mouse antibody (5 nM); and - 3 μL of particles (P4) (1 w / v%).

[0160] After the Cagg cycle is applied to the sample, 3 μL of particles (214) (1% w / v) are added to the medium and the Cagg cycle is applied again.

[0161] The results, shown in Table 11 below, are obtained as a function of the amount of PSA present in the reaction medium.

[0162] [Table 11] At the same PSA concentration, Dodiff3 2 or ΔDO 2 The value of Dodiff3 is higher than in the absence of interfering antibodies. 1 or ΔDO 1 Unlike conventional measurements, the measurement of can detect the presence of interfering molecules, and therefore warnings can be applied to prevent reporting erroneous results.

[0163] FIG. 14 shows the optical density difference Dodiff31 (mDO) in the presence and absence of interfering antibodies.

[0164] The method of the invention may conveniently be carried out in equipment of known type, modified by those skilled in the art according to their own knowledge.

Claims

1. 1. A method for assaying a target analyte (20) in a biological sample in a liquid medium, comprising: a) contacting the biological sample with first magnetic particles (10) having first receptors (101) specific for a first attachment site of the target analyte (20), thereby forming a first complex by binding of the first magnetic particles (10) to the target analyte (20), and if an interfering analyte (30) is present in the sample, the contacting also results in the formation of an interfering complex by non-specific binding of the first magnetic particles (10) to the interfering analyte (30); b. applying and maintaining a first magnetic field to locally aggregate all of the complexes formed in step a., and, if any interfering complexes are present, to aggregate the interfering complexes with each other to form interfering aggregates; c. canceling the first magnetic field applied in step b. and adding to the liquid medium second magnetic particles (11) bearing second receptors (111) specific for a second attachment site of the target analyte (20); d. measuring a first quantity representative of the amount of interfering aggregates in the liquid medium to identify the presence or absence of the interfering aggregates; e. Applying a second magnetic field to bind the second magnetic particles (11) and the first complex to form a second complex (61); f) determining the amount of the second complex (61) formed in step e) as a function of the first amount by measuring a second amount representing the total amount of the interfering aggregates and the second complex (61) in the liquid medium, and inferring therefrom the amount of the target analyte (20) present in the biological sample, and the amount of interfering analytes (30), if any; A method comprising:

2. 2. The assay method according to claim 1, wherein step f. comprises the substep of calculating the difference between the second amount measured in step f. and the first amount measured in step d.

3. 3. The method of claim 1, wherein steps c. and d. are performed substantially simultaneously.

4. 4. The method according to claim 1, wherein step d. is performed after the first magnetic field is turned off and before adding second magnetic particles to the liquid medium.

5. 5. The method according to any one of claims 1 to 4, wherein the magnetic field applied in step b. is maintained for less than 5 minutes, preferably less than 3 minutes.

6. 6. The method of claim 1, wherein the application of the second magnetic field comprises magnetizing at 8 mT for 1 second, followed by three successive magnetization and pause sequences: 15 mT for 60 seconds, 0 mT for 28 seconds, 8 mT for 1 second, and 0 mT for 1 second.

7. 7. The method of claim 1, wherein the measurement of the first and / or second amount is selected from the group consisting of measurement by transmittance nephelometry, measurement by scattering nephelometry, and measurement by counting.

8. 8. The method according to any one of claims 1 to 7, wherein step a. comprises the substep of adding a diluent to dilute the biological sample to make the ratio of sample to diluent 1:10 (by volume) or more.

9. 9. The method of any one of claims 1 to 8, wherein step b. comprises the substep of extracting the first complex from the liquid medium.

10. 10. The method according to any one of claims 1 to 9, wherein step b. comprises a substep b1. of adding a reaction buffer after removing the liquid medium, preferably further comprising at least one wash between removing the liquid medium and adding the reaction buffer.

11. 11. The method of claim 10, wherein the reaction buffer contains at least one anti-aggregating agent and / or cell lysis agent.

12. 12. The method of any one of claims 1 to 11, wherein the sample is a whole blood sample.

13. 13. The method of any one of claims 1 to 12, wherein the interfering aggregate is identified when the first amount exceeds a predetermined threshold amount.

14. Apparatus arranged to carry out the method of any one of claims 1 to 13.

Citation Information

Patent Citations

  • Method and apparatus for measuring particle by using photosound and immunoassay utilizing this method and apparatus

    JP1991110447A

  • Measuring method for antigen and antibody

    JP2000146975A

  • Measurement of aggregation parameters

    JP2010513913A

  • Method of administering the analyte into a liquid medium

    JP2010534829A

  • Apparatus and methods for performing hematological and biochemical measurements from biological samples.

    JP2015508158A